{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:00:20Z","timestamp":1791406820547,"version":"4.3.3"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annemergmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Emergency Medicine"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.annemergmed.2021.01.003","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T04:19:23Z","timestamp":1616818763000},"page":"357-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Third-Generation Cephalosporin Resistance and Associated Discordant Antibiotic Treatment in Emergency Department Febrile Urinary Tract Infections"],"prefix":"10.1016","volume":"78","author":[{"given":"Dustin G.","family":"Mark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Yi","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zena","family":"Salim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole J.","family":"Tarlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley W.","family":"Frazee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annemergmed.2021.01.003_bib1","series-title":"Antibiotic Resistance Threats in the United States, 2019","year":"2019"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.annemergmed.2020.08.022","article-title":"Emergence of extended-spectrum beta-lactamase urinary tract infections among hospitalized emergency department patients in the United States","volume":"77","author":"Talan","year":"2020","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib3","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E\u00a0coli\u00a0or Klebsiella pneumoniae bloodstream infection and ceftriaxone\u00a0resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"issue":"suppl 1","key":"10.1016\/j.annemergmed.2021.01.003_bib4","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1093\/ofid\/ofz004","article-title":"Application of next-generation sequencing for characterization of surveillance and clinical trial isolates: analysis of the distribution of beta-lactamase resistance genes and lineage background in the United States","volume":"6","author":"Mendes","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-resistant bacterial infections in US hospitalized patients, 2012-2017","volume":"382","author":"Jernigan","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib6","article-title":"Infectious Diseases Society of America antimicrobial resistant treatment guidance: gram-negative bacterial infections","author":"Tamma","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib7","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1086\/604713","article-title":"A\u00a0multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients","volume":"49","author":"Ben-Ami","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib8","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.mib.2006.08.011","article-title":"The CTX-M beta-lactamase pandemic","volume":"9","author":"Canton","year":"2006","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/11533040-000000000-00000","article-title":"Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices","volume":"70","author":"Pitout","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib10","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1128\/AAC.02824-14","article-title":"A\u00a0new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131","volume":"58","author":"Banerjee","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib11","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3201\/eid2209.160148","article-title":"Fluoroquinolone-resistant and extended-spectrum beta-lactamase-producing Escherichia coli infections in patients with pyelonephritis, United States","volume":"22","author":"Talan","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.annemergmed.2018.05.006","article-title":"Emergency department urinary tract infections caused by extended-spectrum beta-lactamase\u2013producing enterobacteriaceae: many patients have no identifiable risk factor and discordant empiric therapy is common","volume":"72","author":"Frazee","year":"2018","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220265","article-title":"The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017","volume":"14","author":"Critchley","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib14","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00862-20","article-title":"Escherichia coli resistance to fluoroquinolones in community-acquired uncomplicated urinary tract infection in women: a systematic review","volume":"64","author":"Stapleton","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/21681805.2017.1373698","article-title":"Prediction of infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: development of a clinical decision-making nomogram","volume":"52","author":"Garcia-Tello","year":"2018","journal-title":"Scand J Urol"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib18","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1128\/AAC.00009-11","article-title":"Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system","volume":"55","author":"Tumbarello","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib19","doi-asserted-by":"crossref","first-page":"ofz164","DOI":"10.1093\/ofid\/ofz164","article-title":"A\u00a0clinical prediction tool for extended-spectrum cephalosporin resistance in community-onset Enterobacterales urinary tract infection","volume":"6","author":"Weinstein","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/cid\/ciw283","article-title":"Fecal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae and risk factors among healthy individuals: a systematic review and metaanalysis","volume":"63","author":"Karanika","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib21","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10096-019-03528-9","article-title":"Inappropriate empirical antibiotic therapy does not adversely affect the clinical outcomes of patients with acute pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriales","volume":"38","author":"Kim","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jhm.2157","article-title":"Impact of extended-spectrum beta-lactamase-producing organisms on clinical and economic outcomes in\u00a0patients with urinary tract infection","volume":"9","author":"MacVane","year":"2014","journal-title":"J\u00a0Hosp Med"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib24","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cix606","article-title":"Empiric therapy with carbapenem-sparing regimens for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: results from the INCREMENT Cohort","volume":"65","author":"Palacios-Baena","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib25","doi-asserted-by":"crossref","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","article-title":"Health care\u2013associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections","volume":"137","author":"Friedman","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib26","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/cid\/cis942","article-title":"Community-associated extended-spectrum beta-lactamase-producing Escherichia coli infection in the United States","volume":"56","author":"Doi","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jhin.2019.01.012","article-title":"Clinical prediction models for ESBL-Enterobacteriaceae colonization or infection: a systematic review","volume":"102","author":"Mohd Sazlly Lim","year":"2019","journal-title":"J\u00a0Hosp Infect"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib28","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/cid\/ciw425","article-title":"A\u00a0clinical decision tree to predict whether a bacteremic patient is infected with an extended-spectrum beta-lactamase-producing organism","volume":"63","author":"Goodman","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/archinte.159.1.53","article-title":"Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial","volume":"159","author":"Mombelli","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10096-015-2559-7","article-title":"Correlation between antimicrobial resistance and virulence in Klebsiella pneumoniae","volume":"35","author":"Hennequin","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1128\/CMR.00125-13","article-title":"Escherichia coli ST131, an intriguing clonal group","volume":"27","author":"Nicolas-Chanoine","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib32","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1128\/AAC.49.11.4667-4670.2005","article-title":"Virulence factors of Escherichia coli isolates that produce CTX-M-type extended-spectrum beta-lactamases","volume":"49","author":"Pitout","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib33","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1128\/AAC.04821-14","article-title":"Impact of extended-spectrum beta-lactamase production on treatment outcomes of acute pyelonephritis caused by Escherichia coli in patients without health care\u2013associated risk factors","volume":"59","author":"Park","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib34","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1128\/AAC.50.4.1257-1262.2006","article-title":"Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae","volume":"50","author":"Schwaber","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib35","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1586\/14787210.6.5.751","article-title":"Clinical and economic burden of antimicrobial resistance","volume":"6","author":"Maragakis","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.annemergmed.2021.01.003_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02165-18","article-title":"A\u00a0systematic review of single-dose aminoglycoside therapy for urinary tract infection: is it time to resurrect an old strategy?","volume":"63","author":"Goodlet","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Annals of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064421000317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064421000317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T04:46:28Z","timestamp":1759293988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196064421000317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0196064421000317"],"URL":"https:\/\/doi.org\/10.1016\/j.annemergmed.2021.01.003","relation":{},"ISSN":["0196-0644"],"issn-type":[{"value":"0196-0644","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Third-Generation Cephalosporin Resistance and Associated Discordant Antibiotic Treatment in Emergency Department Febrile Urinary Tract Infections","name":"articletitle","label":"Article Title"},{"value":"Annals of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annemergmed.2021.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American College of Emergency Physicians.","name":"copyright","label":"Copyright"}]}}